EUSA Pharma launches phase III SILVAR study of siltuximab in patients hospitalised with COVID-19

Study will evaluate efficacy & safety of standard of care, both with and without IV siltuximab in patients suffering from serious viral acute respiratory distress syndrome in a hyperinflammatory state, previously treated with corticosteroids or with another respiratory infection.

Source:

PharmaTimes